China Manufacturing Landscape for Mitotane (CAS 53-19-0)
Mitotane (o,p’-DDD) is the cornerstone treatment for adrenocortical carcinoma and remains an orphan drug with a limited global supplier base. As one of China’s qualified qualified manufacturers of this specialized adrenolytic API, our facility in Hubei Province provides a reliable alternative source for pharmaceutical companies formulating Mitotane tablets. The strategic importance of maintaining multiple qualified API sources for orphan oncology drugs makes our manufacturing capability particularly valuable to formulators seeking supply chain diversification.
Our entry into Mitotane production was driven by the recognition that global supply of this essential oncology API was overly concentrated among a small number of manufacturers. By establishing a fully validated, quality-compliant manufacturing process, we offer the pharmaceutical industry much-needed supply security for this life-saving compound.
Manufacturing Process & Facility
Our Mitotane synthesis employs a controlled chemical process starting from commercially available dichlorodiphenyltrichloroethane (DDT) precursors, utilizing selective dechlorination and isomeric purification to produce the therapeutically active o,p’-isomer with high isomeric purity. The process includes multiple recrystallization steps and chromatographic purification to achieve the required specification.
Key facility features:
- Dedicated synthesis suites with containment engineering controls for potent compound handling
- Glass-lined and stainless steel reactors (100L to 2000L) with precise temperature control
- Preparative chromatography systems for isomeric purification
- ISO Class 8 cleanroom environments for final isolation and packaging
- Annual production capacity: 2 metric tons of Mitotane API
- Complete environmental monitoring and waste treatment systems
All manufacturing operations are conducted under contained conditions appropriate for cytotoxic compounds, with validated cleaning procedures and dedicated equipment preventing cross-contamination.
Quality Standards & Multi-Pharmacopeial Compliance
Our Mitotane API is manufactured to meet USP and EP monograph specifications:
| Parameter | Specification | Test Method |
|---|---|---|
| Appearance | White to off-white crystalline powder | Visual |
| Identification | Positive by IR, GC, melting point | IR/GC/DSC |
| Assay | 98.0–102.0% | GC |
| o,p’-DDD Isomeric Purity | ≥97.0% | Chiral GC |
| p,p’-DDD (related isomer) | ≤2.0% | GC |
| Related Substances (total) | ≤1.5% | GC |
| Loss on Drying | ≤0.5% | 105°C, 2h |
| Residual Solvents | Meets ICH Q3C | GC-HS |
| Heavy Metals | ≤10 ppm | ICP-MS |
| Melting Point | 76–78°C | DSC/capillary |
Regulatory Documentation
We provide regulatory support tailored to the orphan drug status of Mitotane:
- US FDA Drug Master File (Type II) — filed and active
- EU ASMF available for customer reference in Marketing Authorization Applications
- China NMPA registration
- Complete process validation package (three consecutive batches)
- ICH Q1A stability studies with 36-month long-term data
- Detailed impurity profile with synthesis and characterization of specified impurities
- Genotoxic impurity assessment per ICH M7
- Environmental risk assessment documentation
Given Mitotane’s orphan drug designation in multiple jurisdictions, our regulatory affairs team is experienced in navigating the specific documentation requirements associated with orphan medicinal products.
Packaging & Logistics
Mitotane is packaged according to requirements for potent active pharmaceutical ingredients:
- Primary: Double polyethylene bags, heat-sealed, within rigid HDPE containers
- Secondary: Fiber drums (5 kg, 10 kg, 25 kg) with appropriate hazard labeling
- Containment packaging meeting potent compound shipping requirements
- Storage: Below 25°C, protected from light and moisture
- Shelf life: 36 months from date of manufacture
Export logistics are managed through experienced pharmaceutical freight forwarders with appropriate dangerous goods handling certifications. We offer FOB, CIF, and DDP shipping terms with full export documentation support.
Competitive Pricing & Supply Reliability
As one of a limited number of qualified global sources for Mitotane API, we emphasize supply reliability alongside competitive pricing:
- Dedicated production equipment eliminating campaign changeover delays
- Strategic raw material inventory ensuring production continuity
- Flexible batch sizes from 10 kg to 500 kg per campaign
- Priority manufacturing allocation for essential medicine supply commitments
We recognize the critical importance of uninterrupted Mitotane supply for adrenocortical carcinoma patients and structure our production planning accordingly. Long-term supply agreements with guaranteed allocation and pricing caps are available. Contact our specialty oncology team for detailed discussions.